SLXNW SILEXION THERAPEUTICS CORP revenue, earnings and financials
For the quarter ended June 30, 2026, SILEXION THERAPEUTICS CORP reported revenue of n/a, net income of −$3.55M and diluted EPS of $5.17; for the fiscal year ended December 2025 revenue was n/a.
SLXNW annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$11.6M, net income −$11.9M (margin n/a), EPS $89.61
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$12.6M, net income −$16.5M (margin n/a), EPS $3955.11
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$4.68M, net income −$5.11M (margin n/a), EPS $659.55
SLXNW quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.55M, EPS $5.17
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.73M, EPS $8.46
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.41M, EPS $5.15
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.26M, EPS $2.88
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.50M, EPS $43.19
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.74M, EPS $38.39
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.75M, EPS $3470.77
- Quarter ended Sep 30, 2024: revenue n/a, net income −$11.9M, EPS $274.25
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.49M, EPS $197.80
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.42M, EPS $12.29
- Quarter ended Sep 30, 2023: revenue n/a, net income −$809K, EPS $0.78
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.88M, EPS $6.54
SLXNW cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$10.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$8.40M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$4.53M, share buybacks n/a
SLXNW balance sheet
- Jun 30, 2026: cash $2.23M, total assets $4.25M, total liabilities $4.20M, shareholders' equity $44.0K
- Mar 31, 2026: cash $2.41M, total assets $4.60M, total liabilities $4.31M, shareholders' equity $291K
- Dec 31, 2025: cash $5.99M, total assets $7.22M, total liabilities $4.61M, shareholders' equity $2.60M
- Sep 30, 2025: cash $9.24M, total assets $11.6M, total liabilities $4.64M, shareholders' equity $6.98M
- Jun 30, 2025: cash $3.47M, total assets $5.80M, total liabilities $5.68M, shareholders' equity $120K
- Mar 31, 2025: cash $6.15M, total assets $8.31M, total liabilities $5.72M, shareholders' equity $2.59M
- Dec 31, 2024: cash $1.19M, total assets $2.86M, total liabilities $6.85M, shareholders' equity −$3.99M
- Sep 30, 2024: cash $1.97M, total assets $3.09M, total liabilities $7.67M, shareholders' equity −$4.58M
Is SLXNW profitable?
No. SILEXION THERAPEUTICS CORP lost $14.0M over the last four quarters.
What is SLXNW's EPS?
Diluted earnings per share over the last four quarters were $21.66; $5.17 in the latest quarter.